Innovative Finance for Health
Exploring Incentives for Neglected Disease R&D
Jonas Ahlén , Peter Lundström , Josephine Rudebeck
Despite all efforts to stimulate research, development and production of drugs against neglected diseases (malaria, tubercolosis etc) efficient and affordable drugs are still lacking. This study, commissioned by Swedish International Development Cooperation Agency, proposes three different areas of possible action: A research program, a bridge finance facility for mid-cycle R&D and a risk mitigation mechanism for late-cycle R&D.